Peripherally inserted central venous catheter in Autologous Hematopoietic Stem Cell Transplantation: Feasibility and Outcome

Authors

DOI:

https://doi.org/10.46765/2675-374X.2023v4n2p197

Keywords:

Hematopoietic stem cell transplant, peripherally inserted central catheter, vascular access devices, blood stream infection, venous thrombosis

Abstract

Objectives: This study describes our experience using PICC in patients submitted to autologous stem cell transplant (ASCT) regarding the time of use, withdrawal reasons, and complications.

Methods: A retrospective cohort of 143 patients from 2017 and 2019, with a PICC inserted before the ASCT.  

Results: Regarding baseline disease, 104 (73%) of patients had multiple myeloma. The median days of use was 15 (1 – 37) per catheter. More than 80% of PICC remained in place after D+15, and 112 (78%) patients had the PICC removed at discharge. Only 13 (9%) patients had replacement of the PICC. The rates of central line associate bloodstream infection and thrombosis were 1.36 and 1.36 events per 1,000 PICC days, respectively.

Conclusions: PICCs were successfully remained until discharge, with manageable rates of complications. All procedures were executed by nurses at the bedside. We concluded that PICC is a safe and feasible alternative to CVC for ASCT.

Author Biography

Marcia Garnica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

I - DASA- Complexo Hospitalar de Niterói, Niterói, RJ, Brazil

II - Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Downloads

Published

06/02/2023

How to Cite

Garnica, M., Valentim, M. R. ., Coelho, T. C., Cardoso Madeira, E. P., Rangel, L. da C. de O. ., Brito, A. P., & Almeida , A. R. (2023). Peripherally inserted central venous catheter in Autologous Hematopoietic Stem Cell Transplantation: Feasibility and Outcome. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 4(2), 197. https://doi.org/10.46765/2675-374X.2023v4n2p197

Issue

Vol. 4 No. 2 (2023): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Section

Original article

License

Copyright (c) 2022 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.